Abigail Pinchbeck

Industry Insights: The adjuvant access problem: barriers to broader vaccine development

A cell therapy safety signal defined the month: Novartis paused eight trials of its experimental CAR-T therapy rap-cel across autoimmune and neurological indications after three deaths from immune effector cell-associated hemophagocytic syndrome, prompting Bristol Myers Squibb to...